Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List
SHANGHAI, China, Dec. 29, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug List (NRDL)